Differential suppression of the human mixed epidermal cell lymphocyte reaction (MECLR) and mixed lymphocyte reaction (MLR) by cis-urocanic acid. 1997

H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
Department of Dermatology, University Hospital Leiden, The Netherlands.

Cis-urocanic acid (UCA), formed in the stratum corneum by UV irradiation of trans-UCA has been proposed as a mediator of UV-induced immunosuppression in the skin. In this study, we examined the in vitro effect of cis-UCA (6-100 micrograms/mL) on the human mixed lymphocyte reaction (MLR) and the mixed epidermal cell lymphocyte reaction (MECLR). Addition of cis-UCA (purified or in a mixture with trans-UCA) did not affect the MLR but was able to induce a 20% suppression of the MECLR responses. Because this effect of cis-UCA on the MECLR was not as strong as could be expected from previous in vivo results, we designed a set of experiments in order to enhance the in vitro immunosuppressive capacity of cis-UCA. Firstly, we preincubated epidermal cells with UCA (50 micrograms/mL). for 3 or 6 days before culture in the MECLR because in vivo repeated UV exposure can lead to a photostationary state, where cis-UCA may be present for several weeks. This pretreatment with cis-UCA resulted in a maximal decrease of the MECLR response of 27%, whereas trans-UCA had no effect. Secondly, we investigated whether UVB irradiation of epidermal cells could make cells more sensitive to cis-UCA. However, addition of trans- or cis-UCA did not potentiate the reduced alloactivating capacity of UVB-irradiated cells. Finally, we examined the possibility of a synergistic effect of cis-UCA with histamine. Addition of histamine suppressed the MLR and MECLR responses, but neither cis- nor trans-UCA were able to modulate this decrease. We conclude that cis-UCA can partly downregulate the human MECLR but not the MLR. The mechanism involved in this differential downregulation is not known. In this respect it is striking that cis-UCA dose not potentiate the UVB- or histamine-induced suppression of the MECLR.

UI MeSH Term Description Entries
D007959 Lymphocyte Culture Test, Mixed Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens. Leukocyte Culture Test, Mixed,Mixed Lymphocyte Culture Test,Mixed Lymphocyte Reaction,Mixed Leukocyte Culture Test,Mixed Leukocyte Reaction,Leukocyte Reaction, Mixed,Leukocyte Reactions, Mixed,Lymphocyte Reaction, Mixed,Lymphocyte Reactions, Mixed,Mixed Leukocyte Reactions,Mixed Lymphocyte Reactions
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006632 Histamine An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. Ceplene,Histamine Dihydrochloride,Histamine Hydrochloride,Peremin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D014560 Urocanic Acid 4-Imidazoleacrylic acid. Glyoxalinylacrylic Acid,Acid, Glyoxalinylacrylic,Acid, Urocanic

Related Publications

H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
January 1985, British journal of clinical pharmacology,
H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
June 1977, Cellular immunology,
H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
February 1983, British journal of clinical pharmacology,
H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
July 1984, British journal of clinical pharmacology,
H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
August 1987, Photo-dermatology,
H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
December 1994, The Journal of investigative dermatology,
H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
February 2003, BMC pregnancy and childbirth,
H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
August 1985, British journal of clinical pharmacology,
H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
April 1984, British journal of clinical pharmacology,
H M Hurks, and C Out-Luiting, and R G Van den Molen, and B J Vermeer, and F H Claas, and A M Mommaas
September 1979, Comptes rendus des seances de l'Academie des sciences. Serie D, Sciences naturelles,
Copied contents to your clipboard!